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the TRUE Dilatation™ Balloon Valvuloplasty Catheter in patients undergoing transcath-
eter aortic valve implantation (TAVI).
Methods: Between January and May 2012, a total of 18 patients (pts) with high grade
aortic stenosis underwent valvuloplasty of the aortic valve using the TRUE Dilatation™
Balloon Valvuloplasty Catheter prior to TAVI. Several performance measures were
evaluated and graded from 1 to 10, which 10 indicating best performance.
Results: Subjects were 83 6 years old, logistic EuroSCORE 16 7%, STS 9.6 4.5.
The mean aortic gradient was 4819mmHg, the valve orifice area was 0.66 0.19 cm2.
BAV was successful in all cases. Neither balloon nor annular rupture occurred in any
case,. Balloon inflation and deflation times were less than 2 seconds, The grade for the
performance measure “ease of catheter insertion through introducer sheath” was 9.30.5
points, 9.10.5 for “ease of passing catheter over aortic arch, ease of catheter crossing
over aortic valve” 9.20.7 points, for “speed of balloon inflation” 9.60.6 points, for
“ability to dilate aortic valve without balloon slippage” 8.91.7 points, and for “speed of
balloon deflation” 8.91.1 points. Five pts (28%) received and Edwards SAPIEN XT and
12 pts (72%) a Medtronic CoreValve Prosthesis after BAV. The 30 day stroke and
mortality rates were zero and 5.6%.
Conclusions: This study shows that the TRUE Dilatation™ Balloon Valvuloplasty
Catheter has an excellent performance with fast inflation and deflation times in patients
with severe aortic stenosis in the absence of harmful side effects.
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Background: Transcatheter aortic valve implantation (TAVI) procedures offer remark-
able benefits for high risk patients with severe aortic stenosis. However, the current TAVI
devices are associated with complications such as lack of repositionability, paravalvular
leakage and atrio-ventricular block. Moreover, there is no long-term clinical data about the
durability of current tissue-derived TAVI prostheses and leaflet degradation during the
loading into the catheter remains a serious concern.
Methods: A new generation transcatheter aortic valve (TAV) has been developed by our
group at University College London. The UCL-TAV benefits from leaflets made of a
novel nanocomposite polymer encompassed by a self-expandable Nitinol stent. The
polymer is composed of a polycarbonate urea urethane soft segment (PCU) and hard
segment derived from polyhedral oligomeric silsesquioxane (POSS) nanoparticles
through covalent bonding forming pendant chain functional groups. POSS-PCU nano-
composite possesses enhanced physiochemical properties, resistance to calcification and
thrombosis with superior in-vivo biostability. It has been successfully implanted in human
in the form of a small calibre bypass graft, lacrimal duct conduit, and more recently as the
world’s first synthetic trachea. The UCL-TAV design allows for multi-stage expansion of
the prosthesis providing controlled deployment, and is fully retrievable in the case of
misplacement.
Results: POSS-PCU demonstrated superior mechanical properties compared to porcine
and bovine pericardial tissues. Initial prototypes of UCL-TAV were successfully pro-
duced using a consistent manufacturing technique, and tested for collapse and re-
expansion over several cycles with no observable structural damage. Owing to its thin
polymeric leaflets membrane, the valve can be crimped in to a catheter equal to or less
than 18 Fr to provide easier vascular access, and the design has improved anchoring and
sealing with no need for excessive radial force.
Conclusions: Having a fully retrievable design as well as an advanced material, the
UCL-TAV can overcome the main limitations of current TAVI devices. The UCL-TAV
is currently under pre-clinical evaluation.
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Background: Percutaneous tricuspid valve implantation has received little attention,
mainly due to the unstructured annulus and the associated difficult stentframe anchoring.
Tricuspid regurgitation is commonly a result of right ventricle-dilation secondary to left
heart diseases. A novel anatomically adapted tricuspid heart valve prosthesis, consisting
of a vena cava superior-stent (CSA) and a tricuspid annulus-stent (ASA) connected by
flexible struts, was developed. Anatomical CT-data of a porcine heart (65 kg, female) was
post-processed using Mimics and 3-matic (Materialise, Leuven, Belgium) and relevant
dimensions were considered in the stent design process. The anchoring of the prosthesis
relies primarily on the CSA-stent and is supported by the valved ASA-stent. First
experience with this anchoring concept, using a design with an additional vena cava
inferior-stent, was gained in animal trials which demonstrated the feasibility of the
concept.
Methods: Finite element simulations were performed with Abaqus (Simulia, Providence,
USA) to analyze the crimping process of the arched stent-construct and the loading on a
straight catheter. A custom trileaflet heart valve was sewn into the 40 mm diameter
ASA-stent, using bovine and porcine pericardium for the leaflets and a sealing skirt,
respectively. The smallest diameter was determined by crimping tests and a catheter was
adapted. The physiological function of the new prosthesis sample was tested in-vitro
inside a mock-loop, specifically designed for the simulation of the right heart. The valved
stent-construct was introduced into an anatomical silicone-model of the right heart to
analyze the adaptation to the heart structure and the prosthesis’ function in-vitro.
Results: The arched stent-construct of a vena cava superior-stent, five struts and a large
valved tricuspid annulus-stent could be crimped to fit the custom delivery catheter system.
The in-vitro tests showed good adaptation, enough flexibility of the struts, good seal and
a physiological pressure of 5/40 mmHg was applied.
Conclusions: The percutaneous tricuspid valve approach was proven to work with two
different designs, one already assessed in animal trials and one successful in in-vitro tests.
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Background: Revalving failed bioprostheses with transcatheter valves cannot be done
routinely because of diminished EOA and concerns for their long-term durability. A
two-part rapidly exchangeable tissue valve has been developed as an alternative. The
design of the valve was inspired by the off-patent features of the Edwards Perimount/
Magna series. It is a two-component valve where the permanent base can be implanted
without the leaflets, improving visibility and hence speed of implant. The removable
leaflet set can later be exchanged via transapical access, off-pump.
Methods: Animal studies have shown calcification resistance superior to the Perimount,
and bench studies show greater EOA than the Magna, and durability greater than 200
million cycles at a closing pressure of 200 mmHg. In its first clinical use, 23-mm size
valves were implanted into three men, two with bicuspid valves and one with senile aortic
valve stenosis. Two were placed with infra-annular pledgets and one with supra-annular
pledgets. The base was inserted first and then the leaflet set was attached with the aid of
clear plastic shields that protected the 2-mm high post.
Results: Placement of the base first allowed easier valve insertion, as tall commissural
posts, found in current pericardial valves were not present to obstruct suture tying.
Furthermore, the absence of leaflets allowed additional infra-valvular sutures to be placed
without difficulty.
Conclusions: This new valve shows promise for easier insertion and good durability. In
addition it may facilitate leaflet-set exchange, should it deteriorate later. Further study
appears to be justified for early and late results.
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Background: A pre-hospital electrocardiogram (ECG) improves the management of
patients with ST-segment elevation myocardial infarction (STEMI). Current telecommu-
nication systems do not permit real-time interaction with first responders in the field or
with care providers at referring hospitals. Our institution has developed a novel
telecommunications system based on a software application that is downloadable to
multiple platforms to permit real-time, two-way video and voice interaction over a
secured, HIPPA compliant network.
Methods: We hypothesized that the use of the CodeHeart application (CHap) for patients
with possible acute coronary syndrome will reduce door-to-balloon (DTB) times of
STEMI patients. Therefore, all STEMI system activations after implementation of the
CHap system, were prospectively entered into a database. Consecutive CHap activations
were compared to routine activations as controls, during the same time period (03/14/2011
to 12/31/2011). System quality measures were calculated and compared using Student’s
t test or the Mann-Whitney U test as appropriate.
Results: A total of 360 STEMI system activations occurred. 62 (17%) employed CHap
and 298 (83%) routine channels. DTB times were reduced by the use of CHap when
compared to controls (95.335’ vs. 154.6102.4’, p0.0009) as were first call-to-
balloon times (68.929.3’ vs. 91.740’, p0.004), which highlights our network’s
response efficiency for transferred patients. The percentage of catheterization laboratory
activations for a true STEMI was higher with the use of CHap, although this trend did not
reach statistical significance. [CHap 38/62 (61.3%) vs. routine 148/298 (49.7%), p0.12].
Conclusions: The implementation of a two-way telecommunications system that allows
for real-time interactions between interventional cardiologists and referring practitioners
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improves overall DTB time and transfer time. In addition, it has the potential to decrease
the frequency of false activations, therefore improving cost-efficiency of a network’s
STEMI system.
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Background: The purpose of this study was to evaluate the safety, feasibility, and results
of using the Tack-It Endovascular Stapler™ to manage post-PTA dissection. Stents are
used to manage of post-PTA dissection of the lower extremity arteries. This generally
provides an acceptable post-intervention angiographic result but has long-term disadvan-
tages such as in-stent restenosis and fracture. Focal treatment of post-PTA dissection and
avoidance of stent placement in this setting is the function of the Tack-It device.
Methods: A total of 15 limbs (11 patients) with 25 lesion treatment sites were treated
with the study device between December, 2009 and March, 2010. In the study group, 7
subjects had lesion treatments in one leg and 4 subjects had lesion treatments treated in
bilateral extremities for lesions of the SFA, popliteal, or tibial arteries or a combination of
these. Indications were CLI in 9 of the 15 limbs and claudication in 6.
Results: Acute technical success for luminal patency at the end of the study procedure
was achieved with Tack placement and tissue apposition in 100% of all treated
dissections. 50 Tacks were placed and placement was accurate in 96% (48/50). Tack
placement successfully provided a smooth, post-angioplasty blood vessel surface and
permanently secured post-PTA dissections. Mean procedure time was 51 minutes (range
10 – 128 minutes). Mean fluoroscopy time was 13 minutes (range 5 – 30 minutes). Two
patients died and 2 were lost to follow-up during the year after the procedure. There were
no device related complications. There were no major limb amputations. 18 of the 25
lesions were available for follow-up at one year. There was recurrent stenosis (50%) in
3 of 18. One patient with gangrene and a popliteal occlusion returned with a recurrent
stenosis at 3 months and required repeat angioplasty and Tack placement for a TLR rate
of 4%. Overall angiographic patency at one year was 83.3%.
Conclusions: Use of the Tack-It Endovascular Stapler™ to manage post-PTA dissec-
tions is safe and feasible, and resulted in permanent securement of dissection flaps without
stent placement and with reasonable angiographic patency at one-year.
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Background: Histotripsy is a novel technique that uses high-amplitude focused ultra-
sound pulses to create cavitation in a targeted tissue, with resultant mechanical breakdown
of the tissue structure. Ultrasound imaging provides feedback for the therapy, including
targeting and monitoring treatment progression. We assessed the feasibility of histotripsy
for ablating large vessel plaque.
Methods: Human plaque specimens obtained from carotid or femoral endarterectomy
were fixed to a gelatin substrate and placed in a water tank. In 4 samples, the focus was
scanned within the plaque to try to create a channel through it. In 3 samples, multiple fixed
focal ablations were performed to evaluate erosion rate. Histological analysis was
performed post treatment to examine ablation efficacy for different plaque types.
Results: Tissue breakdown was evident in most samples. Cavitation was observed by
B-Mode imaging on the surface or within the plaque volume during treatment, indicating
the region of disruption. Channels up to 1 cm were created within the bulk of the plaque.
Ablation rate was strongly dependent on plaque type: fatty material could be ablated
within a few seconds in the focus, while very fibrous material required5-15 minutes per
focal volume. No damage was observed to calcific material. The figure shows gross
morphology (left) and histology (right) of a channel created adjacent to the lumen in a
fibrous-fatty plaque.
Conclusions: Histotripsy provides a noninvasive method of ablation of atherosclerotic
plaque. We are currently exploring the feasibility of this technique for treatment of
femoral-popliteal disease.
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Background: To evaluate the outcomes of hybrid endovascular repair for aortic arch
pathology.
Methods: This study was a retrospective analysis involving patients who underwent
hybrid endovascular repair for aortic arch pathologies.
Results: Twenty-one patients (16 men; mean age, 64.716.2 years) with aortic arch
pathologies were treated by hybrid endovascular repair. The indications for treatment
included increased aneurysm size in 16 cases (71.4%), rupture or impending aneurysmal
rupture in 5 cases (23.8%), and rapid growth of aortic dissection ( 10mm/y) in 1 case
(4.8%). Supra-aortic vessel transposition and stent-graft implantation were achieved in all
cases. Two types of stent-graft was used, as follows: the Seal thoracic stent-graft in 14
patients (66.7%); and the Valiant stent grafts in 7 patients (33.3%). Peri-operative
complications affected 5 patients (23.8%), as follows: bleeding (n4, 19.0%); stroke
(n3, 14.3%); renal failure (n2, 9.5%); vascular injury (n1, 4.8%), and respiratory
failure (n1, 4.8%). Two patients died within 30 days (9.5%). Technical success was
achieved in 15 patients (71.5%). Early endoleaks were noted in 4 patients (19.0%). One
patient died during follow-up (mean, 21.311.6 months) due to a de novo aortic
dissection. Persistent early endoleaks were noted in 4 patients (19.0%); 2 of the 4 patients
were successfully managed with implantation of additional stent-grafts. No late onset
endoleaks were noted.
Conclusions: Hybrid treatment with supra-aortic vessel transposition and endovascular
repair may be an option in frail patients in who open procedures is too risky.
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A New Concept Of Stent: The Multilayer Flow Modulator. First Human
Study In Thoraco Abdominal And Abdominal Aortic Aneurysms.
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Background: Thoraco Abdominal Aortic Aneurysms (TAAA) and Abdominal Aortic
Aneurysms (AAA) are traditionally treated surgically, but more and more by interven-
tional procedures (endografts, fenestrated grafts) with a high technical success rate but
high complications rate (mortality 9-12%, endoleacks 10-20%, branch occlusion 3-11%,
neurological complications 5-11%). We developed a new concept of stent, the Multilayer
TUESDAY, OCTOBER 23, 8:00 AM–10:10 AMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Endovascular Aortic Repair and Thoracic Endovascular Aortic Repair B35
P
O
ST
E
R
S
